nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-21. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Tetra Pak is a Swedish multinational food packaging and processing company headquartered in Switzerland. The company offers packaging, filling machines and processing for dairy, beverages, cheese, ice cream and prepared food, including distribution tools like accumulators, cap applicators, conveyors, crate packers, film wrappers, line controllers and straw applicators. Tetra Pak was founded by Ruben Rausing and built on Erik Wallenberg's innovation, a tetrahedron-shaped plastic-coated paper carton, from which the company name was derived. In the 1960s and 1970s, the development of the Tetra Brik package and the aseptic packaging technology made supply possible without the need for a cold chain, substantially facilitating distribution and storage. From the beginning of the 1950s to the mid-1990s, the company was headed by Rausing's two sons, Hans and Gad, who took the company from a family business with six employees in 1954 to a multinational corporation, operating in more than 160 countries and with over 25,000 employees as of 2021. The company is privately owned by the family of Gad Rausing through the Swiss-based holding company Tetra Laval, which also includes the dairy farming equipment producer DeLaval and the PET bottle manufacturer Sidel.
They were supported by the 123rd Special Tactics Squadron, 173rd Airborne Brigade and several companies of 2nd Battalion, 14th Infantry Regiment, 10th Mountain Division. The original plan called for TF Viking to support the 4th Infantry Division advance from Turkey towards Baghdad but the mission was cancelled when Turkey denied staging rights to the US. Viking was assigned the task of keeping 13 Iraqi armoured and infantry divisions in the north from reinforcing Baghdad, the 10th SFG was to organise the Kurdish Peshmerga to support them. Just as in Afghanistan, SF were the first military units in Iraq after the initial entry of JSOC (Joint Special Operations Command) and the CIA. At H-Hour, Bravo and Charlie companies of 1st Battalion, 5th SFG, crossed the Kuwait border began carrying out operations in western Iraq – joining up with the British and Australian SAS and Delta Force elements to secure H-3 Air Base, as well as securing Ar Rutbah; the 5th SFG also carried out operations in support of forces moving on Karbala Nasiriyah and Al Diwaniyah. On 21 March, ODA 554 of Charlie Company, 2nd Battalion 5th SFG entered Iraq and began carrying out operations in southern Iraq – mainly supporting British forces in the seizure of Basra and surrounding locations, until relieved by G squadron, 22 SAS Regiment.
64A Field Veterinary Service 64B Veterinary Preventive Medicine 64C Veterinary Laboratory Animal Medicine 64D Veterinary Pathology 64E Veterinary Comparative Medicine 64F Veterinary Clinical Medicine 64Z Senior Veterinarian (Immaterial) Warrant
Side effects of enasidenib included nausea, diarrhea, elevated bilirubin and, most notably, differentiation syndrome. Glutaminase (GLS), the enzyme responsible for converting glutamine to glutamate via hydrolytic deamidation during the first reaction of glutaminolysis, can also be targeted. In recent years, many small molecules, such as azaserine, acivicin, and CB-839 have been shown to inhibit glutaminase, thus reducing cancer cell viability and inducing apoptosis in cancer cells. Due to its effective antitumor ability in several cancer types such as ovarian, breast and lung cancers, CB-839 is the only GLS inhibitor currently undergoing clinical studies for FDA-approval.
Sources: en.wikipedia.org
Nearly all animals make use of some form of sexual reproduction. They produce haploid gametes by meiosis; the smaller, motile gametes are spermatozoa and the larger, non-motile gametes are ova. These fuse to form zygotes, which develop via mitosis into a hollow sphere, called a blastula. In sponges, blastula larvae swim to a new location, attach to the seabed, and develop into a new sponge. In most other groups, the blastula undergoes more complicated rearrangement. It first invaginates to form a gastrula with a digestive chamber and two separate germ layers, an external ectoderm and an internal endoderm. In most cases, a third germ layer, the mesoderm, also develops between them. These germ layers then differentiate to form tissues and organs. Repeated instances of mating with a close relative during sexual reproduction generally leads to inbreeding depression within a population due to the increased prevalence of harmful recessive traits. Animals have evolved numerous mechanisms for avoiding close inbreeding. Some animals are capable of asexual reproduction, which often results in a genetic clone of the parent. This may take place through fragmentation; budding, such as in Hydra and other cnidarians; or parthenogenesis, where fertile eggs are produced without mating, such as in aphids.
==== Cold fusion ==== The table below provides cross-sections and excitation energies for cold fusion reactions producing nobelium isotopes directly. Data in bold represents maxima derived from excitation function measurements. + represents an observed exit channel.
In 2016, issues of fairness and the misuse of technology were catapulted into centre stage at machine learning conferences, publications vastly increased, funding became available, and many researchers re-focussed their careers on these issues. The alignment problem became a serious field of academic study. In 2015, AlphaGo, developed by DeepMind, beat the world champion Go player. The program taught only the game's rules and developed a strategy by itself. GPT-3 is a large language model that was released in 2020 by OpenAI and is capable of generating high-quality human-like text. ChatGPT, launched on 30 November 2022, became the fastest-growing consumer software application in history, gaining over 100 million users in two months. It marked what is widely regarded as AI's breakout year, bringing it into the public consciousness. These programs, and others, inspired an aggressive AI boom, where large companies began investing billions of dollars in AI research. According to AI Impacts, about US$50 billion annually was invested in "AI" around 2022 in the U.S. alone and about 20% of the new U.S. computer science PhD graduates have specialised in "AI". About 800,000 "AI"-related U.S. job openings existed in 2022. According to PitchBook research, 22% of newly funded startups in 2024 claimed to be AI companies.
Sources: en.wikipedia.org
=== Leaderless initiation === A number of bacterial mRNAs have no 5'UTR whatsoever, or a very short one. The complete 70S ribosome, with the help of IF2 (recruiting fMet-tRNA), can simply start translating such a "leaderless" mRNA. A number of factors modify the efficiency of leaderless initiation. A 5' phosphate group attached to the start codon seems near-essential. AUG is strongly preferred in E. coli, but not necessarily in other species. IF3 inhibits leaderless initiation. A longer 5'UTR or one with significant secondary structure also inhibits leaderless initiation.
In the Philippines, 7-Eleven was run by the Philippine Seven Corporation (PSC). Its first store, located at the corner of EDSA and Kamias Road in Quezon City, opened on February 29, 1984. On July 28, 1988, PSC transferred the Philippine area license to operate 7-Eleven stores to its affiliate, Phil-Seven Properties Corporation ("PSPC"), together with some of its store properties. In exchange thereof, PSC received 47% of PSPC stock as payment. On May 2, 1996, the stockholders of both PSC and PSPC approved the merger of the two companies to advance PSC group's expansion. On October 30, 1996, Securities and Exchange Commission approved the merger and PSPC was then absorbed by PSC as the surviving entity. In 2000, President Chain Store Corporation (PCSC) of Taiwan, also a licensee of 7-Eleven, purchased the majority shares of PSC and thus formed a strategic alliance for the convenience store industry within the area. In February 2009, 7-Eleven signed a non-exclusive contract with Chevron Philippines to open its stores in selected Caltex gas stations nationwide. In 2012, they opened their first store outside of Luzon in Cebu City, which soon expanded to the other parts of Cebu as well as its neighboring provinces. It was followed with the branch openings in Bacolod in 2013, Iloilo City in 2014, Davao City and Cagayan de Oro in 2015. The number of stores eventually spread from these major cities to smaller towns and provinces near them.
== Products and Services == The company's first product was a dry, synthetic polymer, "DNAstable" (originally “SampleMatrix”), a chemical formulation that stabilized purified DNA at ambient temperature. The company later released RNAstable and CloneStable, dry chemical reagents optimized for stabilizing purified RNA and bacterial plasmid DNA, respectively. In 2007, the German biotechnology company, Qiagen, licensed DNAstable for sale under the trade name QIAsafe. Biomatrica and Qiagen subsequently co-developed QIAsafe Blood, an ambient temperature stabilization reagent for unpurified DNA in whole blood. Later in 2007, Biomatrica released molecular assay enhancement products, PCRboost and STRboost, for enhancement of PCR performed on degraded and trace DNA samples. Liquid versions of DNAstable and RNAstable were launched as DNAstable LD and RNAstable LD in 2011 and 2012, respectively. These liquid products provide more flexibility for diverse experimental formats, including those utilizing automated instrumentation. Biomatrica began commercialization of preanalytical products in 2009 with the launch of its “gard” product line. These products include RNAgard Blood, DNAgard Blood, and DNAgard Tissue and Cells, products designed to stabilize biological samples from collection to analytical testing. In 2013, the company launched a device, DNAgard Saliva, for the collection of salivary DNA samples to be used in a variety of research studies. In 2015, a completely redesigned and improved version of this device was launched under the name DNAgard Saliva HT.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.